Latest News

KOALA Trial Reaches Major Milestone with Commencement of Patient Enrolment

Scrip Article: With Selective Targeting, HaemaLogiX Eyes Crowded Multiple Myeloma Space

MedNous Article: How Antigen Discovery Could Redefine Multiple Myeloma

Beyond Biotech Podcast: Interview with Dr Rosanne Dunn

Green Light for First-in-Human Trial of KMCAR™ T-cell Therapy in Multiple Myeloma

Landmark approval granted for Phase 1 clinical trial of the novel KMCAR™ T-cell immunotherapy in multiple myeloma (KOALA study). The KMCAR™ T-cell treatment is being developed by Hae-maLogiX, in collaboration with world-leading Centre of Excellence in Cellular Immunotherapy at Peter MacCallum Cancer Centre.